Insilico Medicine Announces Breakthrough AI-Discovered Drug Candidate in UAE

Key Business Update: First Preclinical Candidate Drug from UAE Team

Insilico Medicine Cayman TopCo (HKEX: 3696) has announced a significant milestone for its shareholders and potential investors. The company’s UAE team has nominated ISM0387, an MTA-cooperative PRMT5 inhibitor, as its first preclinical candidate drug, marking a notable achievement in its drug discovery pipeline.

Highlights of the Announcement

• First AI-Discovered Preclinical Candidate Drug from UAE: ISM0387 was discovered and developed locally by Insilico Medicine’s UAE team using the company’s proprietary AI-driven Pharma.AI platform.
• Accelerated Discovery Timeline: The entire early discovery workflow—from molecular design to lead compound optimization—was completed in less than 12 months. Notably, a series of hit compounds were generated in just 30 days, and lead compound optimization was finished within 6 months.
• Drug Profile—ISM0387:
  • AI-powered novel structure
  • Improved in vitro activity and selectivity
  • Enhanced brain penetrant properties
  • Robust, dose-dependent efficacy in disease models
  • Exceptional CNS-penetrant abilities, making it a promising treatment for Glioblastoma (GBM), a highly challenging brain cancer
• Strategic Importance: This is Insilico Medicine’s 30th AI-supported preclinical candidate (PCC) to date, further establishing its leadership in AI-powered drug discovery.
• Strong Regional Support: The achievement was publicly recognized and supported by key UAE agencies, including the Emirates Drug Establishment (EDE), the Department of Health (DoH) – Abu Dhabi, and the Abu Dhabi Investment Office (ADIO).

Potential Impact for Shareholders

• Innovation and Speed: The ultra-fast timelines for hit generation and lead optimization (30 days and 6 months, respectively) demonstrate the power of Insilico’s AI platform, which could position the company ahead of competitors in bringing new therapies to market.
• Expansion into New Markets: This is the first preclinical candidate from Insilico’s UAE team, indicating the company’s successful geographic and operational expansion. This diversification could help de-risk the pipeline and open new regional opportunities.
• Therapeutic Focus: ISM0387’s potential as a new treatment for Glioblastoma—a cancer with high unmet need and limited effective therapies—could attract significant interest from global investors and partners if clinical development progresses well.
• Regulatory and Institutional Backing: The visible support from UAE regulatory and investment agencies may facilitate clinical development and potential market access in the Middle East.

Important Considerations and Forward-Looking Risks

• The company cautions that forward-looking statements in the announcement—such as drug development timelines and commercialization prospects—are subject to uncertainties and there is no guarantee of success or regulatory approval.
• The financial and operational data in this announcement have not been audited or reviewed by external auditors.
• Shareholders and potential investors should exercise caution and seek professional advice before making investment decisions based on this update.

Board Leadership and Governance

The announcement is authorized by Dr. Aleksandrs Zavoronkovs (Chairman, Executive Director, CEO, and CBO), with a Board comprising both executive and independent non-executive directors with deep scientific and industry expertise.

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should consult their professional advisors before making investment decisions.

View INSILICO Historical chart here